Factors Associated with Decisions for Initial Dosing, Up-Titration of Propiverine and Treatment Outcomes in Overactive Bladder Syndrome Patients in a Non-Interventional Setting
Two doses of propiverine ER (30 and 45 mg/d) are available for the treatment of overactive bladder (OAB) syndrome. We have explored factors associated with the initial dosing choice (allocation bias), the decision to adapt dosing (escalation bias) and how dosing relative to other factors affects tre...
Main Authors: | Marjan Amiri, Tim Schneider, Matthias Oelke, Sandra Murgas, Martin C. Michel |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-01-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/10/2/311 |
Similar Items
-
Association of diabetes, hypertension, and their combination with basal symptoms and treatment responses in overactive bladder patients
by: A. Elif Müderrisoglu, et al.
Published: (2023-03-01) -
Efficacy and safety of propiverine and terazosine combination for one year in male patients with luts and detrusor overactivity
by: Nevzat Can Sener, et al.
Published: (2013-07-01) -
Correlations of mean voided volume with other parameters of overactive bladder syndrome
by: Fabian Erbing, et al.
Published: (2023-03-01) -
Urodynamic Detrusor Overactivity in Patients with Overactive Bladder Symptoms
by: Mohammed A. Al-Ghazo, et al.
Published: (2011-03-01) -
Botulinum toxin A for the Treatment of Overactive Bladder
by: Po-Fan Hsieh, et al.
Published: (2016-02-01)